B+
Bull case
25%
Probability
Target price
$4.80
Analysis reference price unavailable
Analysis 2026-04-18 · RankAlpha Sentiment Codex
RZLT
RezoluteDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The constructive part of the March 2026 FDA interaction is that the agency did not shut down sunRIZE after the miss and instead asked for a fuller data package, while the company still has a second Phase 3 program, upLIFT, due in H2 2026. If either the congenital HI review or tumor HI readout restores confidence in ersodetug's efficacy path, the stock has room toward the roughly $4.75 sell-side median target.
Posture
Defensive
Lead driver
Sentiment
What changed
Next scheduled catalyst: earnings 2026-09-15 · AMC.
What can break
Dilutive financing risk can return if the congenital HI path stretches or tumor HI data slip
Momentum
37
Value
41
Sentiment
44
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.50 · Bull $4.80 · Bear $2.10Analysis 2026-04-18; returns require an exact persisted reference.
Earnings
2026-09-15 · AMC
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-18 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $8.13
Why
Momentum37 · Δ7d +6.2
Value41 · Δ7d 0.0
Sentiment44 · Δ7d +6.4
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Next scheduled catalyst: earnings 2026-09-15 · AMC.
- • Sentiment remains the lead driver in the composite, 7D delta +6.4.
Contradictions & invalidation
- • Dilutive financing risk can return if the congenital HI path stretches or tumor HI data slip
- • FDA may conclude the submitted datasets are insufficient for a marketing application and require additional work
- • The core bear point is that sunRIZE missed both primary and key secondary endpoints, so the congenital HI path now depends on FDA accepting a post hoc data package and open-label extension evidence rather than a clean pivotal win.
Catalyst clock
2026-09-15 · AMC
FDA review of sunRIZE data package and program path decision
Lead driver: Sentiment · See AI snapshot
Momentum
37
9% active weight
Current posture
7d trendImproving
Δ7d
+6.2
Δ21d
-44.3
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
44
62% active weight
Current posture
7d trendImproving
Δ7d
+6.4
Δ21d
+7.7
Why this grade
Composite grade D. Momentum 36.6 / Value 41.2 / Sentiment 43.6
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-18. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$3.50
Analysis reference price unavailable
Analysis 2026-04-18 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$2.10
Analysis reference price unavailable
Analysis 2026-04-18 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$450.65M
Beta
0.47
Shares Out
96.29M
P/E (TTM) · Derived
-4.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-5.60
Rev YoY
-
EPS YoY
-42.5%
Gross Margin
-
Op Margin
-
Net Debt
-$166.24M
Current Ratio
15.84
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data